三力制药与海南大学签署技术转让合同

Core Viewpoint - The collaboration between Sanli Pharmaceutical and Hainan University aims to enhance resource sharing and innovation in drug research and development, specifically focusing on the compound HXW2324 for Alzheimer's disease treatment [1] Group 1: Contract Details - Sanli Pharmaceutical has signed a technology transfer contract with Hainan University, acquiring the patent application rights for the compound HXW2324 [1] - The total transfer price for the patent rights is set at 200 million RMB, which includes a milestone payment of 20 million RMB and a sales commission of 180 million RMB [1] - The payment will be made in installments, with the first milestone payment contingent upon successful efficacy research on three classic Alzheimer's disease animal models [1] Group 2: Sales and Commission Structure - Upon commercialization of the HXW2324 compound, Sanli Pharmaceutical will pay Hainan University a commission of 2 RMB per box sold, inclusive of VAT [2] - The total sales commission can accumulate to 180 million RMB, or the commission obligation will cease after five years from the first sales commission withdrawal [2]